BioLegend, Inc.

CAMBRIDGE, England--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the appointment of William J. Kullback to its Board of Directors as a Non-Executive Director (NED). Bill is a seasoned executive bringing extensive financial experience from large life science tool manufacturers to Nuclera’s leadership team. He joins the board at a crucial time for Nuclera as the company continues its global commercial expansion strategy following a successful $75 million series C close1. Dr Michael Chen, CEO and co-founder, Nuclera, commented: “I am pleased to welcome Bill to the Nuclera board. His distinguished career and financial expertise will be instrumental as we push forward with our growth strategy in line with our commercial goals. He added: “Bill’s experience will be invaluable to Nuclera as we scale to address current challenges in protein production by bringing eProtein Discovery to even more researchers.” Since August 2023, Bill has held the position of CFO at Telesis Bio, a company specializing in automated synthesis technology for therapeutic discovery, during which time he oversaw the restructuring of operational expenses resulting in a ~70% decrease. He brings over 30 years of experience as a CFO, focusing on financial and manufacturing operations, mergers and acquisitions, and public markets across multiple publicly traded companies. Bill previously served as CFO at BioLegend Inc., a worldwide provider of antibodies and life science reagents, where he helped manage the company’s $5.25 billion sale to NYSE listed Revvity (previously PerkinElmer), the largest acquisition in Revvity’s history. Bill also negotiated and closed acquisitions and investments whilst CFO at NASDAQ listed medical device company, Lombard Medical, prior to its acquisition by Shanghai-based MicroPort Scientific Corporation. He has also held senior financial positions at a range of medical device and life science tools businesses during his career. Bill earned both his MBA and bachelor’s degree from the State University of New York at Buffalo. Bill Kullback, Non-Executive Board Director, Nuclera, added: “Nuclera’s eProtein Discovery has the potential to transform drug discovery workflows. The Company is at an exciting stage as it expands globally and I am looking forward to working with the team to support the Company’s growth and drive success at this pivotal stage in Nuclera’s development.” For more information about Nuclera’s eProtein Discovery system, please visit: https://www.nuclera.com/system/

Scientists at Cincinnati Children's lead deepest dive yet into the mechanics of blood cell development. They found new treasure. CINCINNATI , March 21, 2024 /PRNewswire/ -- Thanks to an unusual application of game theory and machine learning technology, a large team of scientists led by experts at Cincinnati Children's has published the world's most detailed "atlas" of the many types of stem cells and early progenitors involved in producing human blood from diverse donors. Continue Reading A large team of scientists led by experts at Cincinnati Children’s has published the world’s most detailed “atlas” of the many types of stem cells and early progenitors involved in producing human blood from diverse donors. The team has identified more than 80 distinct subsets of hematopoietic stem and progenitor cells (HSPCs) – early-stage cells that kick off production of mature red cells, white cells and other elements of our complex blood system. Details were published March 21, 2024, in Nature Immunology. "We believe our highly focused capture strategy of the earliest HSPCs, intermediate cell states plus stromal populations, and the most abundant end states provides the deepest view of bone marrow stem and progenitor compartments described to date," the co-authors state. The study was led by co-first authors Xuan Zhang, PhD, and Baobao Song, PhD, and co-corresponding authors Nathan Salomonis, PhD, and H. Leighton Grimes, PhD, all researchers with Cincinnati Children's. Overall, the study includes 26 co-authors from four academic medical centers and two biotech companies. Leukemia implications and more This complex research project involved using multiple advanced genomic research tools and computational methods to build detailed genomic and proteomic profiles of more than 300,000 bone marrow cells collected from a diverse mix of donors spanning race and sex. Cincinnati Children's is committed to promoting inclusivity and addressing population diversity in scientific studies as part of their ongoing mission. In addition to meticulous single-cell RNA sequencing work and matching flow cytometry, analyzing the massive data set required innovative use of machine learning technology and dipping into game theory to perform key statistical analyses. Some of the research tools the team used, including two software tools scTriangulate and pyIninityFlow, were developed at Cincinnati Children's. Among the team's key findings: Mixing a new "cocktail" of 132 antibodies that can target surface proteins on HSPCs and related cells. Testing demonstrated that the new mix outperforms commercial products for profiling human bone marrow cells. Identifying 89 clusters by a novel integration of gene expression and surface proteins helped reveal new stem/progenitor cell populations. Strategies and markers for isolating novel cell populations. First, two novel surface markers C5L2 and TSPAN33 to identify cells entering transitional states between progenitor status and becoming a mature neutrophil. Second, distinct staging of human red blood cell formation called erythroblasts with CD326 and CD235a. New online computational tools to predict the cellular origins and possible causes of cancers such as acute myeloid leukemia (AML). "Our analysis uncovers previously hidden cell states, such as the most primitive stem cells, by combining information from diverse prior atlases, surface markers and genes, and new advances in machine learning," Salomonis says. One of the most immediate potential applications of the new stem cell atlas centers on how treatment centers monitor patients receiving therapies for leukemia. "For example, some people develop resistance to Venotoclax with azacytidine (a chemotherapy that was approved in 2018 as a first line therapy for AML)," Grimes says. "In some cases, the therapy-resistant disease appears to be driven by a "monocytic" form of leukemia stem cell (m-LSC) rather than a more "primitive" form (p-LSC). With an atlas like this, it becomes more possible to determine which types of cancer stem cells are present in the AML, and that information could then inform how a clinician might adjust a treatment regimen." The new study reports finding 69 antibodies within 23 cell states that may represent attractive biomarkers for clinical monitoring of people with AML. While the development of the new stem cell atlas is an essential start, much more research and development will be needed to integrate the new data about blood cell formation into medical care, Grimes says. Making the tool available The co-authors predict that the new digital bone marrow atlas will accelerate the discovery of more cellular and molecular regulators of blood diseases. To support such efforts, the research team is making its data and tools widely available to the research community. While the Nature Immunology article has been made open access, full detail and access to this advanced digital resource, including data viewers, methods, raw data and code, are available at . About the study In addition to the first and corresponding authors, contributing co-authors from Cincinnati Children's include Guangyuan Li, Dan Schnell, Kairavee Thakkar, Michal Kouril, Kang Jin, Stuart Hay, and Sidharth Sen, all with the Division of Biomedical Informatics; plus Kyle Ferchen, Bailee Kain, David Bernardicius, Siyuan Ma, and Sierra Bennett, all with the Division of Immunobiology. Data acquisition for this study included support from the Research Flow Cytometry Core and the DNA Sequencing and Genotyping Core at Cincinnati Children's. Contributors also included scientists from the Yale School of Medicine, University of Pittsburgh, University of Colorado School of Medicine, San Diego-based BioLegend Inc., and Massachusetts based Curiox Biosystems, Inc. Funding sources for this work include several grants from the National Institutes of Health, especially an RC2 grant from the NIDDK, complemented by an NIDDK Cooperative Centers of Excellence in Hematology grant, a Specialized Center of Research (SCOR) grant from the Leukemia & Lymphoma Society, and the US Department of Veterans Affairs. SOURCE Cincinnati Children's Hospital Medical Center

Company announces roadmap anchored by new two plate workflow enabling preparation of samples up to 2 million cells and beyond New collaborations with Vizgen, BioLegend, and SPT Labtech will extend range and ease of high parameter research using ScaleBio tools SAN DIEGO--(BUSINESS WIRE)-- Scale Biosciences, Inc. (aka ScaleBio) (ScaleBio™), an innovator in exponentially scaled single-cell sequencing, providing instrument-free workflows and accessible cost, today announced its development of a new two plate workflow to enable dramatic scaling of its technology and a first set of partners to improve ease of use and enable the deployment of their portfolio across new omics applications. The new platform, announced at the 2024 Advances in Genome Biology and Technology (AGBT) general meeting being held February 5-8, 2024 in Orlando, Fla., allows researchers to prepare sequencing-ready single-cell libraries of up to 2 million cells in a experiment and reduces the plates needed from three to two. This technology will form the basis for future ScaleBio innovation and product development. “As we look to the future, we are focused on enabling dramatic scaling of single cell-based experiments with higher throughputs across a wider range of parameters and applications,” said Giovanna Prout, CEO of ScaleBio. “Empowering researchers to discover more is as much about building high-quality tools as it is about working across the industry to expand what’s possible when different types of tools and datasets are brought together. We’re not only adding high throughput capabilities to our kits, we are also working with industry partners to enable new applications of single-cell research and alternate product options.” ScaleBio will initially commercialize their new platform technology as part of a single-cell high parameter protein profiling workflow leveraging BioLegend’s (part of Revvity) highly validated TotalSeq-A™ antibody panels. ScaleBio also plans to incorporate this new platform technology into its single-cell RNA sequencing portfolio, to enable researchers to conduct ultra-high throughput experiments in functional drug screening and other applications, accessing thousands of samples and millions of cells at a time. ScaleBio partners with Vizgen Inc. to support growing demand for integration of single-cell and spatial technologies across omics applications ScaleBio is partnering with Vizgen to give the scientific community more options to combine single-cell and spatial technologies for integrated data analysis. The complementary nature of these methods will allow scientists to understand tissue composition and the roles and interactions of heterogeneous cell types within a tissue for further insights then performing the methods on their own. Bringing these methods together has utility across a variety of applications including neuroscience and cancer biology. At AGBT, the companies will share combined datasets of high-resolution data from mouse brain tissue sections generated using their respective technologies. These datasets will demonstrate the measurements from single-cell RNA-seq and targeted spatial gene expression profiling to identify matching cell types, including all major cell types in the brain and subtypes of neurons. The matched datasets will also allow for integration of Vizgen’s targeted neuronal panel with spatial mapping and cell-typing with ScaleBio’s high-throughput single-cell RNA data which enables profiling of low-abundance cells and non-targeted gene expression to map to the spatial analysis. “Advancing biological research and biomedical innovation requires a wide range of tools and data types to answer increasingly complex research questions,” said Terry Lo, President and CEO of Vizgen. “Partnering with ScaleBio provides our customers with complementary multiomic solutions that work in parallel to offer useful insights about the role of cells within tissues, driving biological discovery.” In partnership with other companies, ScaleBio aims to streamline and improve the customer experience with its products with an eye towards driving efficiency around its existing instrument-free workflow and data analysis. Through a new relationship with SPT Labtech, ScaleBio is working to offer customers an automation option to implement their workflows on SPT Labtech’s firefly® platform by creating plug and play, cloud-based scripts optimized for ScaleBio library preparation protocols. ScaleBio also has a partnership with Basepair to offer the ScaleBio Seq Suite on the Basepair platform. This data analysis offering enables researchers, regardless of in-house bioinformatics capabilities, an easy way to access an optimized bioinformatics pipeline through a user-friendly, web-based tool. Connect with ScaleBio at AGBT Sponsored Talk: The Single Cell Era, Scaled Presenter: Giovanna Prout, CEO, ScaleBio Time: Wednesday, February 7, 2:20 p.m. – 2:40 p.m., ET Location: Palms Ballroom II & III Scientific Talk: Atlas-scale Single-cell DNA Methylation Presenter: Andrew Adey, Ph.D., Professor of Molecular and Medical Genetics, School of Medicine, Oregon Health & Science University Time: Wednesday, February 7, 7:50 p.m.– 8:10 p.m., ET Location: Palms Ballroom II & III Poster #627: Scaling Single-Cell Sequencing: Multiplexing Innovations for Cost-Effective High-Throughput Profiling Presenter: Frank Steemers, Ph.D., Cofounder and Chief Scientific Officer, ScaleBio Time: Wednesday, February 7, 4:45 p.m. – 6:10 p.m., ET Location: Palms Ballroom I Poster #559: Enhanced Single Cell DNA Methylation Analysis Using Combinatorial Indexing Presenter: Margaret Nakamoto, Ph.D., Manager, Product Applications Time: Wednesday February 7, 4:45 p.m. – 6:10 p.m., ET Location: Palms Ballroom I In Suite Poster: Ultra-high Parameter, Instrument-free, Protein Profiling by Sequencing Using TotalSeq™-A Antibodies at Scale Location: Suite Bonaire 6 For more information visit or join us in suite Bonaire 6. About Scale Biosciences ScaleBio is a single-cell sequencing solutions company founded by a multidisciplinary team of scientists and technologists with combined expertise in next-generation sequencing, genomics, proteomics, and bioinformatics, and a common mission for unlocking the potential of single-cell analysis at scale by eliminating barriers to discovery. ScaleBio is financed by leading life sciences tools investors ARCH Venture Partners, BNG01, and Tao Capital. ScaleBio has facilities in San Diego and San Carlos, Calif.